Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allergan Attacks Valeant’s History With Mergers Ahead Of Potential New Offer

This article was originally published in The Pink Sheet Daily

Executive Summary

The Botox-maker wanted to make its case before Valeant could up its offer, which is expected later this week, arguing that Valeant paints a rosier picture than is realistic.

You may also be interested in...



Valeant/Pershing To Allergan: Last Chance To Negotiate

After surprising investors by increasing its bid for Allergan for a second time in one week, Valeant and its activist investor partner Pershing Square, urged management to negotiate before a special meeting is convened to oust the company’s board of directors.

Valeant/Pershing To Allergan: Last Chance To Negotiate

After surprising investors by increasing its bid for Allergan for a second time in one week, Valeant and its activist investor partner Pershing Square, urged management to negotiate before a special meeting is convened to oust the company’s board of directors.

Valeant To Allergan: Anything You Can Do I Can Do Better

The Canadian specialty pharma says its streamlined business model could sufficiently pull costs out of Allergan’s business dealings, including line extensions and post-marketing commitments.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS077256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel